184 related articles for article (PubMed ID: 25178517)
21. Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.
Deeks ED
Drugs; 2017 Feb; 77(2):225-236. PubMed ID: 28105602
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
23. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Barrientos JC; O'Brien S; Brown JR; Kay NE; Reddy NM; Coutre S; Tam C; Mulligan S; Jaeger U; Devereux S; Pocock C; Robak T; Schuster SJ; Schuh A; Gill D; Bloor A; Dearden C; Moreno C; Cull G; Hamblin M; Jones JA; Eckert K; Solman IG; Suzuki S; Hsu E; James DF; Byrd JC; Hillmen P
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):803-813.e7. PubMed ID: 30249389
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Jain P; Thompson PA; Keating M; Estrov Z; Ferrajoli A; Jain N; Kantarjian H; Burger JA; O'Brien S; Wierda WG
Cancer; 2017 Jun; 123(12):2268-2273. PubMed ID: 28171709
[TBL] [Abstract][Full Text] [Related]
25. Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
Cramer P; Fraser G; Santucci-Silva R; Grosicki S; Dilhuydy MS; Janssens A; Loscertales J; Rule S; Goy A; Traina S; Chan EKH; Diels J; Sengupta N; Mahler M; Salman M; Howes A; Chanan-Khan A
Leuk Lymphoma; 2018 Sep; 59(9):2075-2084. PubMed ID: 29295653
[TBL] [Abstract][Full Text] [Related]
26. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
27. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
28. Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
Manukyan G; Turcsanyi P; Mikulkova Z; Gabcova G; Urbanova R; Gajdos P; Smotkova Kraiczova V; Zehnalova S; Papajik T; Kriegova E
Leuk Res; 2018 Sep; 72():113-119. PubMed ID: 30149317
[TBL] [Abstract][Full Text] [Related]
29. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Salles G; Bachy E; Smolej L; Simkovic M; Baseggio L; Panovska A; Besson H; Healy N; Garside J; Iraqi W; Diels J; Pick-Lauer C; Spacek M; Urbanova R; Lysak D; Hermans R; Lundbom J; Callet-Bauchu E; Doubek M
Ann Hematol; 2019 Dec; 98(12):2749-2760. PubMed ID: 31745601
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Kim ES; Dhillon S
Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
[TBL] [Abstract][Full Text] [Related]
31. The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.
Molica S
Expert Rev Hematol; 2013 Oct; 6(5):543-6. PubMed ID: 24083545
[TBL] [Abstract][Full Text] [Related]
32. Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B; Iskierka-Jazdzewska E; Dlugosz-Danecka M; Szymczyk A; Hus M; Szeremet A; Drozd-Sokolowska J; Waszczuk-Gajda A; Zaucha JM; Holojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Osowiecki M; Knopinska-Posluszny W; Dudzinski M; Zawirska D; Subocz E; Halka J; Pluta A; Wichary R; Kumiega B; Budziszewska BK; Jurczak W; Lech-Maranda E; Giannopoulos K; Robak T; Jamroziak K
Anticancer Res; 2020 Jul; 40(7):4059-4066. PubMed ID: 32620653
[TBL] [Abstract][Full Text] [Related]
33. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
[TBL] [Abstract][Full Text] [Related]
34. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
35. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
36. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Sharman JP; Farber CM; Mahadevan D; Schreeder MT; Brooks HD; Kolibaba KS; Fanning S; Klein L; Greenwald DR; Sportelli P; Miskin HP; Weiss MS; Burke JM
Br J Haematol; 2017 Feb; 176(3):412-420. PubMed ID: 27982425
[TBL] [Abstract][Full Text] [Related]
37. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
Herman SE; Mustafa RZ; Jones J; Wong DH; Farooqui M; Wiestner A
Clin Cancer Res; 2015 Oct; 21(20):4642-51. PubMed ID: 26089373
[TBL] [Abstract][Full Text] [Related]
38. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
39. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
40. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
